Financials
Kobayashi Pharmaceutical: 21 fiscal years of results, 2006–2025
- Revenue · FYE Dec 2025
- ¥166bn
- Operating profit · FYE Dec 2025
- ¥15bn
- Net profit · FYE Dec 2025
- ¥3.7bn
- Total assets
- ¥275bn
- Equity ratio
- 76.6%
- Fiscal years on record
- 21 · 2006–2025
This page carries 21 fiscal years of results, from 2006 to 2025. Revenue peaked in 2007 and has not returned to that level since. No year on record closed in a net loss.
Kobayashi Pharmaceutical: long-term performance & turning pointsSales (revenue) and profit-margin ratio
Sales (¥ bn)Net margin (%)| Fiscal year | Unit | 2006 FYE Mar | 2007 FYE Mar | 2008 FYE Mar | 2009 FYE Mar | 2010 FYE Mar | 2011 FYE Mar | 2012 FYE Mar | 2013 FYE Mar | 2014 FYE Mar | 2015 FYE Mar | 2016 FYE Mar | 2016 FYE Dec | 2017 FYE Dec | 2018 FYE Dec | 2019 FYE Dec | 2020 FYE Dec | 2021 FYE Dec | 2022 FYE Dec | 2023 FYE Dec | 2024 FYE Dec | 2025 FYE Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | JPY | ¥247bn | ¥257bn | ¥229bn | ¥126bn | ¥129bn | ¥131bn | ¥131bn | ¥122bn | ¥127bn | ¥128bn | ¥137bn | ¥114bn | ¥148bn | ¥157bn | ¥158bn | ¥151bn | ¥155bn | ¥166bn | ¥174bn | ¥166bn | ¥166bn |
| YoY | % | — | +4.1% | -11.0% | -45.1% | +2.8% | +1.2% | +0.3% | -7.4% | +4.8% | +0.8% | +6.9% | — | +29.7% | +6.4% | +0.6% | -4.9% | +3.2% | +7.1% | +4.3% | -4.6% | +0.1% |
| Operating profit | JPY | ¥17bn | ¥18bn | ¥19bn | ¥16bn | ¥17bn | ¥19bn | ¥19bn | ¥17bn | ¥18bn | ¥18bn | ¥18bn | ¥17bn | ¥23bn | ¥26bn | ¥26bn | ¥26bn | ¥26bn | ¥27bn | ¥26bn | ¥25bn | ¥15bn |
| YoY | % | — | +6.5% | +3.3% | -15.1% | +7.6% | +9.4% | +3.8% | -12.4% | +7.1% | -1.1% | +2.2% | — | +31.6% | +14.8% | -2.3% | +0.8% | +0.8% | +2.3% | -3.4% | -3.5% | -40.2% |
| Ordinary profit | JPY | ¥15bn | ¥15bn | ¥16bn | ¥15bn | ¥17bn | ¥19bn | ¥20bn | ¥19bn | ¥19bn | ¥19bn | ¥18bn | ¥20bn | ¥24bn | ¥27bn | ¥28bn | ¥28bn | ¥28bn | ¥28bn | ¥27bn | ¥27bn | ¥17bn |
| Net profit | JPY | ¥7.5bn | ¥8.3bn | ¥8.5bn | ¥8.9bn | ¥9.2bn | ¥9.3bn | ¥12bn | ¥12bn | ¥12bn | ¥12bn | ¥14bn | ¥14bn | ¥16bn | ¥18bn | ¥19bn | ¥19bn | ¥20bn | ¥20bn | ¥20bn | ¥10bn | ¥3.7bn |
| YoY | % | — | +10.7% | +2.4% | +4.7% | +3.4% | +1.1% | +25.8% | +4.3% | +0.8% | +0.8% | +8.9% | — | +11.2% | +13.2% | +6.1% | +0.5% | +2.6% | +1.5% | +1.5% | -50.2% | -63.4% |
| Operating margin | % | 6.8% | 7.0% | 8.1% | 12.6% | 13.2% | 14.2% | 14.7% | 13.9% | 14.2% | 14.0% | 13.3% | 15.3% | 15.5% | 16.7% | 16.2% | 17.2% | 16.8% | 16.1% | 14.9% | 15.0% | 9.0% |
| Net margin | % | 3.0% | 3.2% | 3.7% | 7.1% | 7.1% | 7.1% | 8.9% | 10.0% | 9.7% | 9.7% | 9.8% | 12.5% | 10.8% | 11.4% | 12.1% | 12.8% | 12.7% | 12.0% | 11.7% | 6.1% | 2.2% |
| Standard | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | Japanese GAAP | |
| Basis | Parent only | Parent only | Parent only | Parent only | Parent only | Parent only | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated |
Cost structure Cost of sales SG&A Operating profit Operating margin
Where each yen of revenue goes — cost of sales, SG&A and what is left as operating profit (¥ bn, stacked)
| Fiscal year | Unit | 2006 *1 FYE Mar | 2007 *1 FYE Mar | 2008 *1 FYE Mar | 2009 *1 FYE Mar | 2010 *1 FYE Mar | 2011 *1 FYE Mar | 2012 *1 FYE Mar | 2013 *1 FYE Mar | 2014 *1 FYE Mar | 2015 *1 FYE Mar | 2016 *1 FYE Mar | 2016 *1 FYE Dec | 2017 *1 FYE Dec | 2018 *1 FYE Dec | 2019 *1 FYE Dec | 2020 *1 FYE Dec | 2021 *1 FYE Dec | 2022 *1 FYE Dec | 2023 *1 FYE Dec | 2024 *1 FYE Dec | 2025 *1 FYE Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | JPY | ¥247bn | ¥257bn | ¥229bn | ¥126bn | ¥129bn | ¥131bn | ¥131bn | ¥122bn | ¥127bn | ¥128bn | ¥137bn | ¥120bn | ¥157bn | ¥167bn | ¥158bn | ¥151bn | ¥155bn | ¥166bn | ¥173bn | ¥166bn | ¥166bn |
| YoY | % | — | +4.1% | -11.0% | -45.1% | +2.8% | +1.3% | +0.3% | -7.3% | +4.7% | +0.8% | +6.9% | — | +30.6% | +6.8% | -5.5% | -4.9% | +3.1% | +7.1% | +4.3% | -4.5% | +0.1% |
| Cost of sales | JPY | ¥167bn | ¥172bn | ¥147bn | ¥57bn | ¥57bn | ¥56bn | ¥55bn | ¥52bn | ¥54bn | ¥55bn | ¥58bn | ¥49bn | ¥61bn | ¥64bn | ¥67bn | ¥65bn | ¥66bn | ¥74bn | ¥77bn | ¥78bn | ¥81bn |
| SG&A | JPY | ¥63bn | ¥67bn | ¥63bn | ¥53bn | ¥55bn | ¥56bn | ¥57bn | ¥53bn | ¥55bn | ¥56bn | ¥61bn | ¥54bn | ¥73bn | ¥77bn | ¥65bn | ¥59bn | ¥63bn | ¥66bn | ¥71bn | ¥63bn | ¥70bn |
| Operating profit | JPY | ¥17bn | ¥18bn | ¥19bn | ¥16bn | ¥17bn | ¥19bn | ¥19bn | ¥17bn | ¥18bn | ¥18bn | ¥18bn | ¥17bn | ¥23bn | ¥26bn | ¥26bn | ¥26bn | ¥26bn | ¥27bn | ¥26bn | ¥25bn | ¥15bn |
| YoY | % | — | +6.8% | +3.0% | -14.8% | +7.7% | +9.3% | +3.6% | -12.4% | +7.2% | -1.1% | +1.9% | — | +31.7% | +14.7% | -2.4% | +1.1% | +0.5% | +2.3% | -3.3% | -3.6% | -40.0% |
| Operating margin | % | 6.8% | 7.0% | 8.1% | 12.6% | 13.2% | 14.2% | 14.7% | 13.9% | 14.2% | 14.0% | 13.3% | 14.5% | 14.6% | 15.7% | 16.2% | 17.2% | 16.8% | 16.0% | 14.9% | 15.0% | 9.0% |
| Change | pp | — | +0.2pp | +1.1pp | +4.5pp | +0.6pp | +1.0pp | +0.5pp | -0.8pp | +0.3pp | -0.2pp | -0.7pp | — | +0.1pp | +1.1pp | +0.5pp | +1.0pp | -0.4pp | -0.8pp | -1.1pp | +0.1pp | -6.0pp |
- *1 Securities report (yuka shoken hokokusho), as filed
Balance sheet Total assets Equity Interest-bearing debt Equity ratio
Total assets, equity and interest-bearing debt (¥ bn), with the equity ratio (%)
| Fiscal year | Unit | 2012 *1 FYE Mar | 2013 *1 FYE Mar | 2014 *1 FYE Mar | 2015 *1 FYE Mar | 2016 *1 FYE Dec | 2016 *1 FYE Mar | 2017 *1 FYE Dec | 2018 *1 FYE Dec | 2019 *1 FYE Dec | 2020 *1 FYE Dec | 2021 *1 FYE Dec | 2022 *1 FYE Dec | 2023 *1 FYE Dec | 2024 *1 FYE Dec | 2025 *1 FYE Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | JPY | ¥148bn | ¥157bn | ¥171bn | ¥186bn | ¥201bn | ¥189bn | ¥219bn | ¥229bn | ¥234bn | ¥238bn | ¥253bn | ¥256bn | ¥267bn | ¥265bn | ¥275bn |
| YoY | % | — | +6.2% | +8.8% | +9.0% | +8.0% | — | +15.8% | +4.5% | +2.2% | +2.0% | +6.0% | +1.3% | +4.6% | -0.8% | +3.8% |
| Equity | JPY | ¥102bn | ¥115bn | ¥127bn | ¥140bn | ¥143bn | ¥142bn | ¥154bn | ¥166bn | ¥173bn | ¥183bn | ¥196bn | ¥198bn | ¥205bn | ¥213bn | ¥211bn |
| YoY | % | — | +12.8% | +10.5% | +10.0% | +2.7% | — | +8.4% | +8.1% | +3.9% | +5.7% | +7.1% | +1.2% | +3.5% | +4.2% | -1.2% |
| Interest-bearing debt | JPY | — | — | — | ¥0.0bn | ¥0.2bn | ¥0.2bn | ¥0.2bn | ¥0.5bn | ¥0.0bn | ¥0.0bn | ¥0.0bn | — | — | — | — |
| Equity ratio | % | 68.9% | 73.1% | 74.3% | 74.9% | 71.2% | 75.1% | 70.3% | 72.7% | 73.9% | 76.6% | 77.4% | 77.4% | 76.6% | 80.4% | 76.6% |
| Change | pp | — | +4.2pp | +1.2pp | +0.6pp | -3.7pp | — | -4.8pp | +2.4pp | +1.2pp | +2.7pp | +0.8pp | 0.0pp | -0.8pp | +3.8pp | -3.8pp |
- *1 Securities report (yuka shoken hokokusho), as filed
Cash flow Operating CF Investing CF Financing CF
Cash generated by operations, spent on investment and raised or repaid in financing (¥ bn)
| Fiscal year | Unit | 2006 *1 FYE Mar | 2007 *1 FYE Mar | 2008 *1 FYE Mar | 2009 *1 FYE Mar | 2010 *1 FYE Mar | 2011 *1 FYE Mar | 2012 *1 FYE Mar | 2013 *1 FYE Mar | 2014 *1 FYE Mar | 2015 *1 FYE Mar | 2016 *1 FYE Mar | 2016 *1 FYE Dec | 2017 *1 FYE Dec | 2018 *1 FYE Dec | 2019 *1 FYE Dec | 2020 *1 FYE Dec | 2021 *1 FYE Dec | 2022 *1 FYE Dec | 2023 *1 FYE Dec | 2024 *1 FYE Dec | 2025 *1 FYE Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | JPY | ¥13bn | ¥8.8bn | ¥12bn | ¥13bn | ¥15bn | ¥13bn | ¥17bn | ¥9.2bn | ¥14bn | ¥15bn | ¥14bn | ¥16bn | ¥22bn | ¥20bn | ¥20bn | ¥24bn | ¥22bn | ¥32bn | ¥18bn | ¥11bn | ¥26bn |
| YoY | % | — | -32.9% | +38.0% | +5.4% | +19.2% | -14.0% | +31.0% | -46.4% | +46.2% | +14.3% | -7.2% | — | +38.8% | -10.5% | +0.4% | +19.4% | -6.5% | +42.4% | -42.5% | -38.7% | +127.5% |
| Investing CF | JPY | -¥6.4bn | -¥12bn | -¥6.4bn | -¥1.4bn | -¥4.7bn | -¥8.4bn | -¥2.9bn | -¥27bn | -¥7.0bn | -¥4.5bn | -¥11bn | -¥0.5bn | ¥7.0bn | -¥8.1bn | -¥5.1bn | -¥13bn | ¥8.0bn | -¥14bn | -¥20bn | -¥18bn | -¥0.2bn |
| Financing CF | JPY | -¥1.4bn | -¥2.4bn | -¥5.3bn | -¥4.4bn | -¥1.8bn | -¥5.2bn | -¥3.3bn | -¥3.7bn | -¥3.8bn | -¥5.2bn | -¥10bn | -¥12bn | -¥9.2bn | -¥4.3bn | -¥15bn | -¥6.0bn | -¥10bn | -¥21bn | -¥19bn | -¥7.8bn | -¥7.9bn |
| Cash & equivalents | JPY | ¥24bn | ¥19bn | ¥17bn | ¥24bn | ¥33bn | ¥32bn | ¥43bn | ¥22bn | ¥26bn | ¥32bn | ¥25bn | ¥28bn | ¥49bn | ¥56bn | ¥56bn | ¥61bn | ¥82bn | ¥79bn | ¥60bn | ¥46bn | ¥65bn |
| YoY | % | — | -21.9% | -10.1% | +38.7% | +37.0% | -2.0% | +34.0% | -47.9% | +16.0% | +25.1% | -21.5% | — | +71.9% | +14.8% | +0.6% | +8.7% | +34.1% | -3.1% | -24.9% | -23.0% | +40.7% |
- *1 Securities report (yuka shoken hokokusho), as filed
Key ratios Operating margin Net margin ROE Equity ratio
Profitability and balance-sheet strength (%). ROE uses year-end equity.
| Fiscal year | Unit | 2006 *1 FYE Mar | 2007 *1 FYE Mar | 2008 *1 FYE Mar | 2009 *1 FYE Mar | 2010 *1 FYE Mar | 2011 *1 FYE Mar | 2012 *1 FYE Mar | 2013 *1 FYE Mar | 2014 *1 FYE Mar | 2015 *1 FYE Mar | 2016 *1 FYE Dec | 2017 *1 FYE Dec | 2018 *1 FYE Dec | 2019 *1 FYE Dec | 2020 *1 FYE Dec | 2021 *1 FYE Dec | 2022 *1 FYE Dec | 2023 *1 FYE Dec | 2024 *1 FYE Dec | 2025 *1 FYE Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | % | 6.8% | 7.0% | 8.1% | 12.6% | 13.2% | 14.2% | 14.7% | 13.9% | 14.2% | 14.0% | 14.5% | 14.6% | 15.7% | 16.2% | 17.2% | 16.8% | 16.0% | 14.9% | 15.0% | 9.0% |
| Change | pp | — | +0.2pp | +1.1pp | +4.5pp | +0.6pp | +1.0pp | +0.5pp | -0.8pp | +0.3pp | -0.2pp | +0.5pp | +0.1pp | +1.1pp | +0.5pp | +1.0pp | -0.4pp | -0.8pp | -1.1pp | +0.1pp | -6.0pp |
| Net margin | % | 3.0% | 3.2% | 3.7% | 7.0% | 7.2% | 7.1% | 8.9% | 10.0% | 9.7% | 9.7% | 11.9% | 10.1% | 10.8% | 12.1% | 12.8% | 12.7% | 12.0% | 11.7% | 6.1% | 2.2% |
| Change | pp | — | +0.2pp | +0.5pp | +3.3pp | +0.2pp | -0.1pp | +1.8pp | +1.1pp | -0.3pp | 0.0pp | +2.2pp | -1.8pp | +0.7pp | +1.3pp | +0.7pp | -0.1pp | -0.7pp | -0.3pp | -5.6pp | -3.9pp |
| ROE | % | — | — | — | — | — | — | 11.5% | 10.6% | 9.7% | 8.9% | 10.1% | 10.3% | 10.8% | 11.1% | 10.5% | 10.1% | 10.1% | 9.9% | 4.7% | 1.7% |
| Change | pp | — | — | — | — | — | — | — | -0.9pp | -0.9pp | -0.8pp | +1.2pp | +0.2pp | +0.5pp | +0.3pp | -0.6pp | -0.4pp | 0.0pp | -0.2pp | -5.2pp | -3.0pp |
| Equity ratio | % | — | — | — | — | — | — | 68.9% | 73.1% | 74.3% | 74.9% | 75.1% | 70.3% | 72.7% | 73.9% | 76.6% | 77.4% | 77.4% | 76.6% | 80.4% | 76.6% |
| Change | pp | — | — | — | — | — | — | — | +4.2pp | +1.2pp | +0.6pp | +0.2pp | -4.8pp | +2.4pp | +1.2pp | +2.7pp | +0.8pp | 0.0pp | -0.8pp | +3.8pp | -3.8pp |
- *1 Securities report (yuka shoken hokokusho), as filed
Revenue in US dollars Revenue (US$m)
The revenue line above, converted at the average ¥/US$ rate of each figure’s own year — never today’s.
Between 2006–2025, Kobayashi Pharmaceutical’s revenue grew 0.7-fold in yen (-2.1% a year). Converted at each year’s own average rate, the same span is 0.5-fold in dollars (-3.4% a year), from $2.1bn to $1.1bn. The dollar figure grew more slowly because the yen weakened over the period: part of the growth an investor sees in yen does not survive translation into dollars.
| Fiscal year | Unit | 2006 *4 FYE Mar | 2007 *4 FYE Mar | 2008 *4 FYE Mar | 2009 *4 FYE Mar | 2010 *4 FYE Mar | 2011 *4 FYE Mar | 2012 *4 FYE Mar | 2013 *4 FYE Mar | 2014 *4 FYE Mar | 2015 *4 FYE Mar | 2016 *4 FYE Dec | 2016 *4 FYE Dec | 2017 *4 FYE Dec | 2018 *4 FYE Dec | 2019 *4 FYE Dec | 2020 *4 FYE Dec | 2021 *4 FYE Dec | 2022 *4 FYE Dec | 2023 *4 FYE Dec | 2024 *4 FYE Dec | 2025 *4 FYE Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | USD | $2.1bn | $2.2bn | $2.2bn | $1.3bn | $1.5bn | $1.6bn | $1.6bn | $1.2bn | $1.2bn | $1.1bn | $1.3bn | $1.0bn | $1.3bn | $1.4bn | $1.5bn | $1.4bn | $1.4bn | $1.3bn | $1.2bn | $1.1bn | $1.1bn |
| YoY | % | — | +2.8% | +1.5% | -39.3% | +9.5% | +11.4% | +0.3% | -24.3% | -3.4% | -11.9% | +18.9% | — | +25.9% | +8.1% | +1.9% | -2.9% | +0.4% | -10.5% | -2.5% | -11.5% | +1.3% |
| Revenue as filed | JPY | ¥247bn | ¥257bn | ¥229bn | ¥126bn | ¥129bn | ¥131bn | ¥131bn | ¥122bn | ¥127bn | ¥128bn | ¥137bn | ¥114bn | ¥148bn | ¥157bn | ¥158bn | ¥151bn | ¥155bn | ¥166bn | ¥174bn | ¥166bn | ¥166bn |
| Rate applied | ¥/US$ | ¥116.28 | ¥117.77 | ¥103.33 | ¥93.53 | ¥87.77 | ¥79.78 | ¥79.79 | ¥97.60 | ¥105.84 | ¥121.02 | ¥108.84 | ¥108.84 | ¥112.16 | ¥110.40 | ¥109.01 | ¥106.78 | ¥109.78 | ¥131.37 | ¥140.51 | ¥151.50 | ¥149.65 |
- *1 1949-1971: Fixed Bretton Woods peg ¥360/$ (Dodge Line 1949; Smithsonian ¥308 from Dec 1971).
- *2 1972: Smithsonian peg ¥308/$ (held until Feb 1973 float).
- *3 1973-1979: JIL (Japan Institute for Labour Policy and Training) g0001.xlsx — fiscal-year (Apr–Mar) basis, integer-rounded. PROVISIONAL; upgrade to BOJ FXERM07 calendar-year later.
- *4 1980-2026: Bank of Japan stat-search FM08'FXERM07 (Tokyo market, USD/JPY spot, 17:00 fixing, monthly average) — calendar-year average of monthly averages.
- *5 Provisional — part-year average, not a full calendar year.
Reporting basis
Which accounting standard each stretch of the series was filed under, and whether the accounts are consolidated.
The series crosses 2 reporting regimes — parent-only Japanese GAAP for 2006–2011; and consolidated Japanese GAAP for 2012–2025. Figures are not strictly comparable across a change of basis: consolidation in particular adds subsidiaries that were previously outside the accounts.
| Fiscal years | Standard | Basis | Years |
|---|---|---|---|
| 2006–2011 | Japanese GAAP | parent-only | 6 |
| 2012–2025 | Japanese GAAP | consolidated | 15 |
All figures are in Japanese yen as filed. Where a foreign-currency comparison is needed elsewhere on this site, yen amounts are converted at the average rate of each figure's own year — not today's rate. Exchange rates & sources →
Read the company history → 日本語版（詳細）— full financial data in Japanese →
Data API
Kobayashi Pharmaceutical’s history, financials, executives and
shareholders are published as static JSON — no key, plain GET.
Full specification →
/api/4967/manifest.json ·/api/4967/history.json ·/api/4967/timeline.json ·/api/4967/decisions.json ·/api/4967/executives.json ·/api/4967/shareholders.json ·/api/4967/financials.json ·/api/4967/financials-longterm.json ·/api/4967/segments.json ·/api/4967/regions.json ·/api/4967/workforce.json · /api/4967/decisions/{slug}.json